spasms

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Abstract Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies. The EMA-C trial (Experimental Medicine in ADHD-Cannabinoids) was a pilot randomised placebo-controlled experimental study of …

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Read More »

Sep 24 2019

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis

ABSTRACT These studies demonstrate transdermal administration of CBD has long-lasting therapeutic effects without psychoactive side-effects. Thus, use of topical CBD has potential as effective treatment of arthritic symptomatology. At present, one in five (21%) adults worldwide are diagnosed with some form of arthritis by their physicians (Helmick et al., 2008). The data presented suggest transdermal …

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis Read More »

Aug 26 2019

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

ABSTRACT The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. …

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Read More »

Aug 26 2019

Medical Marijuana and Epilepsy

ABSTRACT Studies in the U.S. of Epidiolex (a plant-based CBD formulation) have been ongoing for a number of years. Data from these studies has helped provide evidence that led to the FDA approval of this product on June 25, 2018. Epidiolex is a purified (> 98% oil-based) CBD extract from the cannabis plant. It is …

Medical Marijuana and Epilepsy Read More »

Aug 26 2019

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Medical Marijuana and Epilepsy

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.